Abstract
BackgroundGlioblastoma (GBM) is the most common and aggressive adult primary brain malignancy, with a median overall survival of 15 months post-diagnosis. Clinically, GBM is refractory to T cell immune checkpoint...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
